

(43) International Publication Date
12 March 2015 (12.03.2015)(10) International Publication Number
WO 2015/032782 A1

(51) International Patent Classification:

A61M 5/315 (2006.01) *A61M 5/24* (2006.01)
A61M 5/20 (2006.01)

(21) International Application Number:

PCT/EP2014/068655

(22) International Filing Date:

3 September 2014 (03.09.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

13182763.6 3 September 2013 (03.09.2013) EP

(71) Applicant: **SANOFI** [FR/FR]; 54 rue La Boétie, F-75008 Paris (FR).(72) Inventors: **PLUMPTRE, David Aubrey**; 36 Shire Way, Droitwich Spa Worcestershire WR9 7RQ (GB). **BILTON, Simon Lewis**; 47 Wathen Road, Leamington Spa Warwickshire CV32 5UY (GB).(74) Agent: **GEPPERT, Susanne**; Sanofi-Aventis Deutschland GmbH, Global Intellectual Property Department, Industriepark Höchst, Geb. K 703, 65926 Frankfurt am Main (DE).(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: PEN TYPE DRUG INJECTION DEVICE WITH DOSE LIMITING NUT TO PREVENT SETTING OF A DOSE HIGHER THAN THE AMOUNT OF DRUG REMAINING

Fig. 2



(57) Abstract: The present invention relates to a pen type drug injection device (1; 101) with drive mechanism, comprises a housing (4, 5; 104, 105), a dose dial member (6; 106), a drive member (8; 108) engaging a lead screw (9; 109), a first clutch (18; 118) rotationally coupling the drive member (8; 108) and the housing in a coupled state and allowing relative rotation between the drive member and the housing in a de-coupled state, a second clutch (19; 119) rotationally coupling the drive member and the dial member in a coupled state and allowing relative rotation between the drive member and the dial member in a de-coupled state, and a nut (11; 111) coaxially arranged between the drive and the dial member and splined or keyed to the drive as well as threadedly engaged to the dial member, such that it moves axially on the drive member during dose setting but not during dose dispensing, and such that it eventually abuts an end stop on one of the drive or dial member, thereby limiting movement of the nut and preventing setting of a dose larger than the amount of drug remaining in the cartridge.

**PEN TYPE DRUG INJECTION DEVICE WITH DOSE LIMITING NUT TO PREVENT
SETTING OF A DOSE HIGHER THAN THE AMOUNT OF DRUG REMAINING**

5

The present invention relates to a drive mechanism which is suitable for an injection device, especially a pen type drug delivery device. The mechanism comprises a housing, a dial member, a drive member engaging a lead screw, a first clutch rotationally coupling the drive member and the housing in a coupled state and allowing relative rotation between the drive member and the housing in a de-coupled state, a second clutch rotationally coupling the drive member and the dial member in a coupled state and allowing relative rotation between the drive member and the dial member in a de-coupled state, a nut and an end stop limiting movement of the nut. Further, the present invention relates to an injection device comprising such a drive mechanism and a cartridge containing a medicament.

15

An injection device as defined above is known e.g. from EP 1 974 761 B1 wherein the nut is keyed to an outer main housing and may be advanced along a thread on a drive sleeve. When a final dose dispensed position is reached, a radial stop formed on a surface of the nut abuts a radial stop on a surface of the drive sleeve, preventing both the nut and the drive sleeve from rotating further.

20

In addition, a drive mechanism including a torsion spring is known from EP 1 909 870 B1. This device comprises a limiter which is coupled to a driver and a piston rod such that relative rotation between the driver and the piston rod during dose setting causes the limiter to move towards a stopping position wherein the limiter prevents setting of a dose which exceeds the amount of a medicament in a reservoir in the injection device. As the piston rod has a small diameter compared with the driver and the torsion spring, limiting actuation of the device and thus withstanding a relatively high torque via the piston rod may be difficult in some cases.

25

30

As a further alternative, EP 1 570 876 B1 suggests a limiting mechanism for an injection device which prevents the setting of a dose exceeding the amount of liquid left in a cartridge of the injection device. The mechanism comprises a nut member and a cylindrical driver provided with a helical thread at its outer surface, the helical thread having an end defining a threadlength which is related to the total amount of medicine in the cartridge. The nut member is provided with a thread engaging said helical thread of the driver. This mechanism

35

requires that a dose setting member is screwed outward in a housing when rotated to set a dose and it is pressed into said housing when the dose is injected or when rotated to reduce a too large set dose. In some cases, this requirement may be considered as a drawback.

5 WO 2008/031235 A1, WO 2009/070911 A1 and WO 2009/105909 A1 disclose mechanisms with a nut located between a driver and a dial member. The dial member is moved axially for dose dispensing. In addition, WO 2012/125876 A1 discloses a mechanism with a nut located between a driver and a dial member with the driver moving axially during dose setting and/or dose resetting.

10 It is an object of the present invention to provide an improved alternative to the above solutions. Especially, it is an object of the present invention to provide a drive mechanism and an injection device with a reliable mechanism which prevents the setting of a dose exceeding a predefined threshold, e.g. the amount of medicament left in a cartridge of the injection device.

15 This object is solved by a drive mechanism with the features of claim 1. According to the present invention, the nut is rotationally constrained to the drive member and threadedly engaged to the dial member. In other words, the nut is located between the dial member and the drive member such that the nut may not be rotated relative to the drive member and is coupled to the dial member via a threaded interface. Thus, if the drive member is coupled to the housing via the first clutch and the dial member is rotated, e.g. during dose setting or dose resetting, the nut will move with respect to the dial member guided by the threaded interface. On the other hand, if the second clutch prevents any relative rotation between the dial member and the drive member, the nut will maintain its rotational position with respect to the drive member and the dial member. The end stop may be provided at a position which allows abutment or interaction of the nut and the end stop as soon as a predefined threshold is reached. Typically, this may be a maximum settable dose, e.g. the amount of medicament left in a cartridge of the injection device. If the nut abuts the end stop, no further relative rotation between the dial member and the drive member is possible. Thus, irrespective of the state of the second clutch, the drive mechanism and the injection device may be blocked to prevent setting of a higher or further dose and/or to prevent dose dispensing. According to a preferred embodiment, abutment of the nut and the end stop prevents setting of a dose which exceeds the amount of a medicament in a reservoir in the injection device.

The general function of a drive mechanism as defined above is to set a dose and to subsequently dispense the set dose. Dose setting (dose dialling) usually requires a user to manipulate one element of the drive mechanism, preferably to rotate a dial member e.g. via a dial grip. During dose dispensing the dial member may move, e.g. rotate, back to its original position wherein a drive member, which is not actuated during dose setting is moved together with the dial member during dose dispensing. The movement of the drive member may be a rotation, a displacement or a combined movement e.g. along a helical path. The drive member may act on a lead screw which functions as a piston rod for expelling medicament from a cartridge during dose dispensing.

In addition to this basic function of a drive mechanism it is in some cases preferred to allow a resetting of an already set dose, i.e. a correction or a deselecting of a dose. Preferably the user simply has to rotate the dial member, e.g. via a dial grip, in the opposite direction compared to the rotation during dose setting. Preferably, the drive member is not actuated during dose resetting, either.

According to a preferred, optional feature of the present invention, during dose setting (dialling) and dose resetting (deselecting) neither the dial member nor the drive member move axially with respect to the housing. Taking into account that the nut is intended to block the mechanism, to prevent for example setting of a dose which exceeds the amount of a medicament in a reservoir in the injection device, relative axial movement of the dial member and the drive member may cause malfunctions or decrease accuracy of this mechanism. In addition, it is preferred to provide the dial member such that it does not move axially during any operation of the mechanism. This may prevent unintended axial movement of the nut, too. If the dial member does not move axially, a dial extension, i.e. lengthening of the device during dose setting, is unlikely to occur.

To allow rotation of components of the mechanism, it is preferred if the components are mainly located concentrically about a common longitudinal axis of the drive mechanism.

Thus, the components may have a tubular or sleeve-like shape. For example, the nut, the drive member and the dial may each be a tubular element with the nut surrounding the drive member and the dial member surrounding the nut (and thus the drive member). As an alternative, the nut may be designed as a half-nut, i.e. a ring segment.

Further, although it is desirable to reduce the total number of components of a drive mechanism, it might be useful for manufacturing reasons to split one or more components into

separate elements. For example, a housing may comprise an outer body and an insert and/or an inner body which is axially and/or rotationally constrained to the outer body. In addition, a clutch may be designed by providing protrusions and/or recesses directly on the components which are to be coupled or decoupled by the clutch. As an alternative, a separate clutch
5 element may be provided interposed between the two components which have to be coupled or decoupled.

The present invention is directed to a drive mechanism which may be used in an injection device. An injection device usually further comprises a cartridge holder and a cartridge containing medicament to be dispensed. In a reusable injection device, the cartridge holder may
10 be detachable from the drive mechanism to exchange an empty cartridge by a new one. As an alternative, in a disposable injection device the cartridge holder and the cartridge are firmly attached to the drive mechanism such that the whole injection device has to be discarded after a number of doses have been dispensed from the cartridge.

15 In the following, the distal end of an injection device or drive mechanism is referred to as the end where the cartridge and e.g. a needle are located, whereas the opposite end is the proximal end. A dose button may be provided at the proximal end.

20 According to one aspect of the present invention, the nut is guided axially displaceable on the drive member. This may be achieved by a splined interface between the nut and the drive member. For example, the nut may be provided with an axially extending groove or notch on its radially inner surface whereas the drive member is provided with at least one corresponding axial rib or a protrusion on its radially outer surface. As an alternative, the drive member
25 may be provided with one or more recesses and the nut may be provided with at least one protrusion (spline).

Preferably, the nut has an external thread engaging an internal thread of the dial member such that relative rotation between the drive member and the dial member during dose setting causes the nut to move towards the end stop. In an alternative arrangement of the drive
30 mechanism, the dial member and the drive member may perform a relative rotation during dose dispensing such that abutment of the nut and the end stop would prevent further dose dispensing.

35 The threaded interface between the dial member and the nut may be a full thread, i.e. extending over more than 360°. This thread may be either self-locking or not self-locking. To

reduce the overall length of the drive mechanism, it is preferred to choose a relatively small pitch for the threaded interface, e.g. less than 2 mm, preferably less than 1 mm. If the dial member is a tubular element and the threaded interface is provided on a radially inner surface of the dial member, the internal thread of the dial member preferably comprises a plurality of thread segments which extend over less than 180°. With this design of the threaded interface, manufacture of the dial member is possible using a very simple open and shut mould tool construction (without any spinning elements).

Preferably, the end stop is provided on the dial member. This makes abutment of the nut and the end stop independent from possible relative axial movements between the drive member and the dial member. As an alternative, the end stop may be provided on the drive member. The end stop may be a rotational stop, an axial stop or a combination thereof. A rotational stop is preferred due to its increased accuracy compared with an axial stop.

According to an aspect of the present invention, during dose setting and dose resetting the first clutch is in its coupled state and the second clutch is in its de-coupled state. Thus, the drive member is rotationally fixed to the housing and the dial member is allowed to rotate relative to the drive member during dose setting and dose resetting. A spring or any other elastically deformable element may be provided which biases during dose setting and dose resetting the first clutch in its coupled state and/or the second clutch in its de-coupled state. In an embodiment of the invention the biasing may act to pull the second clutch into its coupled state, which is not a permanent coupled state, i.e. it can be overcome with user applied torque.

In a preferred embodiment, the second clutch comprises a ratchet clicker with teeth having in the clockwise and the anti-clockwise direction different ramped tooth angles such that the teeth are allowed to override each other in the de-coupled state of the second clutch with a different resistance in the clockwise and the anti-clockwise direction, and wherein during dose setting and dose resetting the teeth of the second clutch engage in the de-coupled state but are allowed to override each other by an axial movement against the force of an elastic member, e.g. a spring. To act as a ratchet clicker in its de-coupled state, the second clutch is arranged such that its teeth are in loose engagement in the de-coupled state. In other words, the second clutch is fully engaged in the coupled state preventing any relative rotation between the drive member and the dial member, whereas a relative rotation of the drive member relative to the dial member is possible in the de-coupled state with the teeth of the ratchet clicker overriding each other to provide a tactile and/or audible feedback to a

user. Due to the different ramped tooth angles of the ratchet clicker teeth the sound generated by the teeth overriding each other may be different in the clockwise and the anti-clockwise direction. The second clutch located between the drive member and the dial member thus provides two functions: on the one hand, the second clutch allows or prevents relative rotation between the drive member and the dial member and on the other hand it provides a ratchet clicker in the de-coupled state of the second clutch. Hence, less parts or components are required for the drive mechanism according to the present invention.

Preferably, during dose dispensing the first clutch is in its de-coupled state allowing relative rotation between the drive member and the housing and the second clutch is in its coupled state rotationally constraining the dial member and the drive member. This provides a drive mechanism which is based on the principle that the drive member and the dial member rotate relative to each other during dose setting and dose resetting, whereas the drive member and the dial member rotate together during dose dispensing. Thus, the dial member preferably rotates during dose dispensing and entrains the drive member which actuates the lead screw.

There are different ways to couple or de-couple the first clutch. According to a preferred embodiment, the first clutch is coupled and de-coupled by axially displacing the drive member relative to the housing. As an alternative, the drive member may be rotated and/or a separate component may be moved relative to the housing, i.e. displaced and/or rotated. According to a further embodiment of the present invention, the drive mechanism comprises a trigger clutch which is held rotationally fixed and axially displaceable within the housing. The first clutch may be de-coupled by axially displacing the trigger clutch relative to the drive member.

To actuate the trigger clutch, the drive mechanism preferably comprises a trigger pivotably attached to the housing. The trigger may engage the trigger clutch such that swiveling of the trigger relative to the housing axially displaces the trigger clutch.

The first clutch may comprise releasable locking means provided either directly on the drive member and/or the housing or on one or more separate components connected to the drive member and/or the housing. Preferably, the first clutch comprises at least one spline on an outer surface of the drive member and at least one corresponding notch on an inner surface of the housing or on an inner surface of a housing insert. As an alternative, notches may be provided on an outer surface of the drive member while an inner surface of the housing is

provided with corresponding splines. In other words, the first clutch is preferably provided radially with respect to the drive member and the housing.

Generally, the second clutch may be provided in a similar way as described above with respect to the first clutch. However, it is preferred if the second clutch comprises face teeth on a front edge of the drive member and corresponding face teeth on a front edge of the dial member or on a front edge of a separate component like a clutch plate. Further, the face teeth may be provided on a flange or shoulder of the drive member and/or the dial member or a clutch plate. Thus, the second clutch is provided rather axially with respect to the drive member and the dial member.

According to one embodiment of the present invention a clutch plate is provided which is rotationally fixed to the dial member. The clutch plate may be further axially fixed to the dial member. The clutch plate forms part of the second clutch wherein the second clutch is coupled and de-coupled by axially displacing the clutch plate relative to the drive member. In other words, the second clutch may be coupled by pressing the clutch plate firmly to the drive member to prevent the teeth of the ratchet clicker from overriding each other.

In a preferred embodiment of the present invention the mechanism further comprises a spring assisting dose dispensing. This may be e.g. a torsion spring fixed between the housing and the dial member such that energy is accumulated in the torsion spring upon rotation of the dial member relative to the housing. Energy stored in the spring is released during dose dispensing, e.g. by the spring actuating the dial member.

For this embodiment it is preferred if the teeth of the ratchet clicker of the second clutch have a steeper ramped tooth angle in the rotational direction in which the torsion spring biases the dial member and have a shallower ramped tooth angle in the opposite rotational direction. The torsion spring of the drive mechanism accumulates energy upon rotation of the dial member relative to the housing and relative to the drive member. To store this accumulated energy, it is necessary to prevent the dial member from undesired back winding. This is achieved by the steeper ramped tooth angle of the ratchet clicker teeth which are designed such that the torque of the torsion spring is too small to force the teeth of the ratchet clicker to override each other in the coupled state and the de-coupled state of the second clutch. On the other hand, due to the shallower ramped tooth angle in the opposite rotational direction, the torque required by a user to set a dose, and thus straining the torsion spring, is relatively small. To reduce an already set dose, the user has to overcome the higher resistance of the

steeper ramped tooth angle of the ratchet clicker teeth, however, this rotation to reduce a set dose is assisted by the torque of the torsion spring such that the overall user torque required to reduce a set dose is again relatively small.

5 According to a further aspect of the present invention, the drive mechanism comprises a display member which is guided in threaded engagement within the housing. The display member is preferably rotationally fixed to the dial member and displaceable relative to the dial member in axial direction. For example corresponding splines and grooves may be provided on the display member and the dial member. The display member is marked with a
10 sequence of numbers which are visible through a window or an aperture in the housing to denote the dialled dose. In addition, the display member may have the function of providing end stops for dose setting, dose resetting and/or dose dispensing. In other words, the display member may be moved between two positions defining a zero dose stop and a maximum settable dose stop.

15 In addition or as an alternative to the above, the display member may comprise a flexible element wherein the housing or the trigger clutch may comprise a counter element. The flexible element may contact the counter element at the end of dose dispensing to create an audible and/or tactile feedback. Thus, the flexible element and the counter element together
20 indicate that dose dispensing is completed. Preferably, the counter element is provided on the trigger clutch such that upon swiveling of the trigger relative to the housing the counter element is moved into the path which is described by the flexible element of the display member during dose dispensing. The feedback at the end of dose dispensing is thus only provided if the trigger is actuated.

25 According to a further aspect of the present invention, the housing further comprises a unidirectional ratchet or preferably helical stop features cooperating with the drive member wherein the drive member and the lead screw are in threaded engagement. The helical stop features preferably has a ramp profile which is matched to the helical pitch of the threaded
30 engagement of the drive member and the lead screw. Thus, the drive member rotates along a helical path defined by the helical stop feature profile and thus travels helically up the lead screw which remains stationary relative to the housing. The spacing of the teeth of the helical stop features corresponds to the drive member rotation required to deliver a single unit of medicament. Hence, when the drive member is rotated by one unit, axial separation is gen-
35 erated between the teeth of the helical stop features corresponding to the lead screw displacement required to dispense one unit. The axial force provided by the torsion spring which

is applied to the drive member acts directly on the lead screw tending to displace the drive member and lead screw to reengage the helical stop features. The stop feature interface improves dose accuracy as they provide a consistent lead screw axial position which is insensitive to variation in the rotational position of the drive member as defined by the first clutch.

The object of the present invention is further solved by an injection device according to claim 14. An injection device may comprise a drive mechanism as mentioned above and a cartridge containing a medicament, wherein the nut prevents setting of a dose exceeding the amount of a medicament in the cartridge. Preferably, the end stop defines the length of a track on which the nut travels during dose setting, wherein the length of the track corresponds to the total amount of medicament in the cartridge.

The term „medicament“, as used herein, means a pharmaceutical formulation containing at least one pharmaceutically active compound,

wherein in one embodiment the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a proteine, a polysaccharide, a vaccine, a DNA, a RNA, , an enzyme, an antibody or a fragment thereof, a hormone or an oligonucleotide, or a mixture of the above-mentioned pharmaceutically active compound,

wherein in a further embodiment the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis,

wherein in a further embodiment the pharmaceutically active compound comprises at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy,

wherein in a further embodiment the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative, glucagon-like peptide (GLP-1) or an analogue or derivative thereof, or exendin-3 or exendin-4 or an analogue or derivative of exendin-3 or exendin-4.

Insulin analogues are for example Gly(A21), Arg(B31), Arg(B32) human insulin; Lys(B3),
 Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human
 insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein
 5 in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human
 insulin; Des(B27) human insulin and Des(B30) human insulin.

Insulin derivates are for example B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-
 des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin;
 10 B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human
 insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl- ThrB29LysB30
 human insulin; B29-N-(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N-(N-
 lithocholyl-Y-glutamyl)-des(B30) human insulin; B29-N-(ω -carboxyheptadecanoyl)-des(B30)
 human insulin and B29-N-(ω -carboxyheptadecanoyl) human insulin.

Exendin-4 for example means Exendin-4(1-39), a peptide of the sequence H-His-Gly-Glu-
 Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-
 Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂.

20 Exendin-4 derivatives are for example selected from the following list of compounds:

H-(Lys)₄-des Pro₃₆, des Pro₃₇ Exendin-4(1-39)-NH₂,
 H-(Lys)₅-des Pro₃₆, des Pro₃₇ Exendin-4(1-39)-NH₂,
 des Pro₃₆ Exendin-4(1-39),
 25 des Pro₃₆ [Asp₂₈] Exendin-4(1-39),
 des Pro₃₆ [IsoAsp₂₈] Exendin-4(1-39),
 des Pro₃₆ [Met(O)₁₄, Asp₂₈] Exendin-4(1-39),
 des Pro₃₆ [Met(O)₁₄, IsoAsp₂₈] Exendin-4(1-39),
 des Pro₃₆ [Trp(O₂)₂₅, Asp₂₈] Exendin-4(1-39),
 30 des Pro₃₆ [Trp(O₂)₂₅, IsoAsp₂₈] Exendin-4(1-39),
 des Pro₃₆ [Met(O)₁₄ Trp(O₂)₂₅, Asp₂₈] Exendin-4(1-39),
 des Pro₃₆ [Met(O)₁₄ Trp(O₂)₂₅, IsoAsp₂₈] Exendin-4(1-39); or

des Pro₃₆ [Asp₂₈] Exendin-4(1-39),
 35 des Pro₃₆ [IsoAsp₂₈] Exendin-4(1-39),
 des Pro₃₆ [Met(O)₁₄, Asp₂₈] Exendin-4(1-39),

des Pro36 [Met(O)14, IsoAsp28] Exendin-4(1-39),
 des Pro36 [Trp(O2)25, Asp28] Exendin-4(1-39),
 des Pro36 [Trp(O2)25, IsoAsp28] Exendin-4(1-39),
 des Pro36 [Met(O)14 Trp(O2)25, Asp28] Exendin-4(1-39),
 5 des Pro36 [Met(O)14 Trp(O2)25, IsoAsp28] Exendin-4(1-39),
 wherein the group -Lys6-NH2 may be bound to the C-terminus of the Exendin-4 derivative;

or an Exendin-4 derivative of the sequence

des Pro36 Exendin-4(1-39)-Lys6-NH2 (AVE0010),
 10 H-(Lys)6-des Pro36 [Asp28] Exendin-4(1-39)-Lys6-NH2,
 des Asp28 Pro36, Pro37, Pro38 Exendin-4(1-39)-NH2,
 H-(Lys)6-des Pro36, Pro38 [Asp28] Exendin-4(1-39)-NH2,
 H-Asn-(Glu)5des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-NH2,
 des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,
 15 H-(Lys)6-des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,
 H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,
 H-(Lys)6-des Pro36 [Trp(O2)25, Asp28] Exendin-4(1-39)-Lys6-NH2,
 H-des Asp28 Pro36, Pro37, Pro38 [Trp(O2)25] Exendin-4(1-39)-NH2,
 H-(Lys)6-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-NH2,
 20 H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-NH2,
 des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
 H-(Lys)6-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
 H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
 H-(Lys)6-des Pro36 [Met(O)14, Asp28] Exendin-4(1-39)-Lys6-NH2,
 25 des Met(O)14 Asp28 Pro36, Pro37, Pro38 Exendin-4(1-39)-NH2,
 H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
 H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
 des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
 H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
 30 H-Asn-(Glu)5 des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
 H-Lys6-des Pro36 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-Lys6-NH2,
 H-des Asp28 Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25] Exendin-4(1-39)-NH2,
 H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
 H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-NH2,
 35 des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
 H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(S1-39)-(Lys)6-

NH₂,

H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O₂)25, Asp28] Exendin-4(1-39)-
(Lys)6-NH₂;

- 5 or a pharmaceutically acceptable salt or solvate of any one of the afore-mentioned Exendin-4 derivative.

Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008, Chapter 50, such as
10 Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatotropine (Somatotropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, Goserelin.

A polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low
15 molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof. An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.

20 Antibodies are globular plasma proteins (~150 kDa) that are also known as immunoglobulins which share a basic structure. As they have sugar chains added to amino acid residues, they are glycoproteins. The basic functional unit of each antibody is an immunoglobulin (Ig) monomer (containing only one Ig unit); secreted antibodies can also be dimeric with two Ig units as with IgA, tetrameric with four Ig units like teleost fish IgM, or pentameric with five Ig units,
25 like mammalian IgM.

The Ig monomer is a "Y"-shaped molecule that consists of four polypeptide chains; two identical heavy chains and two identical light chains connected by disulfide bonds between cysteine residues. Each heavy chain is about 440 amino acids long; each light chain is about
30 220 amino acids long. Heavy and light chains each contain intrachain disulfide bonds which stabilize their folding. Each chain is composed of structural domains called Ig domains. These domains contain about 70-110 amino acids and are classified into different categories (for example, variable or V, and constant or C) according to their size and function. They have a characteristic immunoglobulin fold in which two β sheets create a "sandwich" shape,
35 held together by interactions between conserved cysteines and other charged amino acids.

There are five types of mammalian Ig heavy chain denoted by α , δ , ϵ , γ , and μ . The type of heavy chain present defines the isotype of antibody; these chains are found in IgA, IgD, IgE, IgG, and IgM antibodies, respectively.

5 Distinct heavy chains differ in size and composition; α and γ contain approximately 450 amino acids and δ approximately 500 amino acids, while μ and ϵ have approximately 550 amino acids. Each heavy chain has two regions, the constant region (CH) and the variable region (VH). In one species, the constant region is essentially identical in all antibodies of the same isotype, but differs in antibodies of different isotypes. Heavy chains γ , α and δ have a
10 constant region composed of three tandem Ig domains, and a hinge region for added flexibility; heavy chains μ and ϵ have a constant region composed of four immunoglobulin domains. The variable region of the heavy chain differs in antibodies produced by different B cells, but is the same for all antibodies produced by a single B cell or B cell clone. The variable region of each heavy chain is approximately 110 amino acids long and is composed of a single Ig
15 domain.

In mammals, there are two types of immunoglobulin light chain denoted by λ and κ . A light chain has two successive domains: one constant domain (CL) and one variable domain (VL). The approximate length of a light chain is 211 to 217 amino acids. Each antibody contains
20 two light chains that are always identical; only one type of light chain, κ or λ , is present per antibody in mammals.

Although the general structure of all antibodies is very similar, the unique property of a given antibody is determined by the variable (V) regions, as detailed above. More specifically,
25 variable loops, three each the light (VL) and three on the heavy (VH) chain, are responsible for binding to the antigen, i.e. for its antigen specificity. These loops are referred to as the Complementarity Determining Regions (CDRs). Because CDRs from both VH and VL domains contribute to the antigen-binding site, it is the combination of the heavy and the light chains, and not either alone, that determines the final antigen specificity.

30 An “antibody fragment” contains at least one antigen binding fragment as defined above, and exhibits essentially the same function and specificity as the complete antibody of which the fragment is derived from. Limited proteolytic digestion with papain cleaves the Ig prototype into three fragments. Two identical amino terminal fragments, each containing one entire L
35 chain and about half an H chain, are the antigen binding fragments (Fab). The third fragment, similar in size but containing the carboxyl terminal half of both heavy chains with their inter-

chain disulfide bond, is the crystalizable fragment (Fc). The Fc contains carbohydrates, complement-binding, and FcR-binding sites. Limited pepsin digestion yields a single F(ab')₂ fragment containing both Fab pieces and the hinge region, including the H-H interchain disulfide bond. F(ab')₂ is divalent for antigen binding. The disulfide bond of F(ab')₂ may be
5 cleaved in order to obtain Fab'. Moreover, the variable regions of the heavy and light chains can be fused together to form a single chain variable fragment (scFv).

Pharmaceutically acceptable salts are for example acid addition salts and basic salts. Acid addition salts are e.g. HCl or HBr salts. Basic salts are e.g. salts having a cation selected
10 from alkali or alkaline, e.g. Na⁺, or K⁺, or Ca²⁺, or an ammonium ion N⁺(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group. Further examples of pharmaceutically acceptable salts are described in "Remington's Pharmaceutical Sciences" 17. ed. Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa., U.S.A., 1985
15 and in Encyclopedia of Pharmaceutical Technology.

Pharmaceutically acceptable solvates are for example hydrates.

20 The present invention will now be described in further detail with reference to the accompanying schematic drawings, wherein

Figure 1 shows an exploded view of an injection device comprising a drive mechanism according to a first embodiment of the invention,

25 Figure 2 shows a section view of the drive mechanism of Figure 1,

Figure 3 shows a further section view of the drive mechanism of Figure 1 with two enlarged details,

30 Figure 4 shows a section view of a further detail of the drive mechanism of Figure 1,

35 Figures 5a, 5b show further section views of the drive mechanism in different states,

Figure 6 shows a perspective view of components of the drive mechanism of Figure 1,

Figure 7 shows an exploded view of an injection device with a drive mechanism according to a second embodiment of the invention,

Figure 8 shows a section view of the drive mechanism of Figure 7,

Figure 9 shows a section view of the drive member of the drive mechanism of Figure 7,

Figures 10a, 10b show perspective views of the inner body of the drive mechanism of Figure 7,

Figure 11 shows a detail of the drive member and the dial member of the drive mechanism of Figure 7,

Figures 12a, 12b show section views of two states of a trigger of the drive mechanism of Figure 7,

Figures 13a, 13b show perspective views of two states of the trigger according to Figures 12a, 12b,

Figure 14 shows a section view of the drive mechanism of Figure 7,

Figure 15 shows a detail of the drive member of the drive mechanism of Figure 7,

Figures 16a to 16c show section views of a ratchet of the drive mechanism of Figure 7 in different positions,

Figure 17 shows a further detail of the drive member of the drive mechanism of Figure 7.

An injection device 1 according to the present invention is shown in Figure 1 in an exploded view. The injection device 1 comprises a cartridge holder 2, a cartridge 3 and a drive mechanism. The drive mechanism comprises an outer housing 4, an inner housing 5, a dose dial

sleeve as a dial member 6, a number sleeve as a display member 7, a drive sleeve as a drive member 8, a lead screw 9, a bearing 10, a nut 11, a drive spring 12, a return spring 13, a dial grip 14, a dose button 15 and a clutch plate 16. All components are located concentrically about a common principle axis of the mechanism. In more detail, the drive member 8 surrounds the lead screw 9, the torsion spring 12 surrounds the drive member 8, the dial member 6 and the inner housing 4 surround the torsion spring 12, the display member 7 surrounds the dial member 6 and the outer housing 4 surrounds the display member 7. Further, the nut 11 and the clutch plate 16 are located between the drive member 8 and the dial member 6.

The dose button 15 is axially constrained to the clutch plate 16. As can be seen in Figure 2, this may be achieved by a snap-on connection with the clutch plate 16 having an opening for receiving a pin of the dose button 15. Thus, the dose button 15 may be rotatable with respect to the clutch plate 16.

The dial grip 14 is axially constrained to the outer housing 4 which forms a body for the drive mechanism. Again, as shown in Figure 3, this may be achieved by a snap-on connection between the dial grip 14 and the outer housing 4. The dial grip 14 is rotationally constrained to the clutch plate 16. In the embodiment of Figures 1 to 6 a splined interface is provided between the dial grip 14 and the clutch plate 16. This splined interface is disconnected when the dose button 15 is pressed, i.e. when the dose button 15 and the clutch plate 16 are moved axially relative to the dial grip 14 and the outer housing 4.

The clutch plate 16 is further rotationally constrained to the dial member 6. Again, a splined interface may be provided between the clutch plate 16 and the dial member 6. The clutch plate 16 is further coupled to the drive member 8 via a ratchet interface which occurs on axial abutment. The ratchet interface provides a detented position between the dial member 6 and the drive member 8 corresponding to each dose unit and engages different ramped tooth angles during clockwise and anti-clockwise relative rotation between the dial member 6 and the drive member 8. This ratchet interface forms the second clutch 19 with corresponding teeth 19a, 19b provided on the clutch plate 16 and the drive member 8, respectively.

The display member 7 is rotationally constrained to the dial member 6. Again, a splined interface may be provided between the display member 7 and the dial member 6. The display member 7 is further constrained to move along a helical path relative to the inner housing 5. This may be achieved by a threaded interface between the display member 7 and the inner

housing 5. As an alternative, a threaded interface may be provided between display member 7 and the outer housing 4. The display member 7 is marked with a sequence of numbers which are visible through a window 17 in the outer housing 4. As an alternative to a transparent window an aperture could be provided in the outer housing 4. The window 17 allows the user to denote the dialed dose of medicament. The window 17 may be or may comprise a magnifying lens. The window 17 may be an integral part of the outer housing 4 or a separate component attached to the housing.

The nut 11 acts as a last dose nut and is interposed between the dial member 6 and the drive member 8. The nut 11 is rotationally constrained to the drive member 8, e.g. via a splined interface. Thus, the nut 11 may be axially displaced relative to the drive member 8. The nut 11 moves along a helical path relative to the dial member 6, e.g. via a threaded interface, when relative rotation occurs between the dial member 6 and the drive member 8, i.e. during dose setting and dose resetting. An end stop (not shown) may be provided to limit the movement of the nut 11 in the track defined by the threaded interface.

The drive member 8 extends from the interface from the dial member 6 down to a splined tooth interface with the inner housing 5. This provides rotational constraint of the drive member 8 to the inner housing 5. The releasable splined tooth interface between the drive member 8 and the inner housing 5 forms the first clutch 18 with teeth 18a, 18b provided on the dial member 6 and the drive member 8, respectively.

When the dose button 15 is pressed, the splined teeth of the first clutch 18 are disengaged and a ratchet feature 20 is engaged which provides an audible and/or tactile feedback during dose dispensing.

The inner housing 5 is rigidly fixed to the outer housing 4. Thus, neither any rotation nor any axial movement between the inner housing 5 and the outer housing 4 is possible. The inner housing 5 and the outer housing 4 may be formed as one integral part, however due to manufacturing reasons it is preferred to provide the housing as the two separate components of the outer housing 4 and the inner housing 5.

The drive spring 12 is a torsion spring which is attached at one end to the inner housing 5 and at the other end to the dial member 6. The drive spring 12 is pre-wound upon assembly, such that it applies a torque to the dial member 6 when the mechanism is at zero units di-

alled. The action of rotating the dial grip 14 to set a dose rotates the dial number 6 relative to the inner housing 5 and winds up the drive spring 12.

5 The lead screw 9 is rotationally constrained to the drive member 8 e.g. via a splined interface. When rotated, the lead screw 9 is forced to move axially relative to the drive member 8. This is achieved by a threaded interface between the lead screw 9 and the inner housing 5. The bearing 10 is axially constrained to the lead screw 9 and acts on the bung within the cartridge 3 during dose dispensing.

10 The axial position of the drive member 8, the clutch plate 16 and the dose button 15 is defined by the action of the return spring 13 which abuts the inner housing 5 and applies a force on the drive member 8 in the proximal direction. This ensures that the clutch plate 16 is in splined engagement with the dial grip 14 and that the drive member 8 is in splined engagement with the inner housing 5. The return spring 13 also acts to maintain the engagement of the ratchet features between the drive member 8 and the clutch plate 16, i.e. to
15 maintain the engagement of the second clutch 19. As an alternative, the function of the return spring 13 may be achieved fully or in part by the torsion spring 12.

20 The outer housing 4 provides location for the cartridge 3 and the cartridge holder 2 which can be attached to the outer housing 4. Further, the outer housing 4 comprises an interface to rigidly constrain the inner housing 5 and a groove on its external surface to axially retain the dial grip 14. Further, a removable cap may be provided which fits over the cartridge holder 2 and is retained via clip features.

25 The dial member 6 is axially interposed between inner housing 5 and dial grip 14 is axially constrained to the outer housing 4. Thus, dial member 6 is axially constrained to the housing 4, 5.

30 In the following, the functions and interactions of the above mentioned components will be described in more detail together with an explanation of the use of the drive mechanism of the injection device 1.

35 Regarding the first clutch 18 and the second clutch 19 there are two generally distinct states of the drive mechanism of the injection device 1 which are shown in Figures 5a and 5b, respectively. Figure 5a shows the drive mechanism in an at rest condition which is a condition if a user does not exert any forces on the drive mechanism. In this at rest condition the

first clutch 18 couples the drive member 8 to the inner housing 5 and the second clutch 19 allows a relative rotation between the clutch plate 16 and the drive member 8. However, to rotate the clutch plate 16 with respect to the drive member 8, a torque has to be provided to overcome the resistance of the ratchet feature, i.e. the clutch plate 6 is not freely rotatable with respect to the drive member 8. The second condition which is shown in Figure 5b occurs if a user depresses dose button 15. This decouples the first clutch 18 such that the drive member 8 is free to rotate with respect to the inner housing 5 and the second clutch 19 is coupled to prevent a relative rotation between the drive member 8 and the clutch plate 16.

With the device in the at rest condition, the display member 7 is positioned against its zero dose abutment with the inner housing 5 and the dose button 15 is not depressed. A dose marking "0" on the dial member 7 is visible through the window 17 on the outer housing 4. The drive spring 12 which has a number of pre-wound turns applied to it during assembly of the device applies a torque to the dial member 6. The dial member 6 is prevented from rotating under the action of the torque by its ratchet interface (second clutch 19) with the drive member 8. The drive member 8 is prevented from rotating by the interlock provided by the engagement of splined teeth 18a, 18b on the drive member 8 and the inner housing 5 (first clutch 18). This is shown in Figure 3. As can be seen in the enlarged details of Figure 3, return spring 13 maintains the first clutch 18 in its coupled state by pushing the drive member 8 in the proximal direction. However, the drive member 8 is free to be displaced in the distal direction against the force of the return spring 13 as the teeth 19a, 19b of the second clutch 19 override each other upon a relative rotation between the drive member 8 and the clutch plate 16. As can be seen in Figure 3, the height of the teeth of the second clutch 19 is smaller than the axial height of the splines of the first clutch 18. Thus, the first clutch 18 remains in its coupled state even if the teeth of the second clutch 19 override each other.

The user selects a variable dose of medicament by rotating the dial grip 14 clockwise which generates an identical rotation in the dial member 6. Rotation of the dial member 6 causes wind up of the drive spring 12, increasing the energy stored within it. The drive member 8 is still prevented from rotating due to the engagement of its splined teeth 18a, 18b with the inner housing 5 (first clutch 18 coupled). A relative rotation must therefore occur between the clutch plate 16 and the drive member 8 via the ratchet interface of the second clutch 19.

The user torque required to rotate the dial grip 14 is a sum of the torque required to wind up the drive spring 12 and the torque required to overhaul the ratchet feature of the second clutch 19. The return spring 12 is designed to provide an axial force to the ratchet feature

and to bias the components (drive member 8, clutch plate 16, dose button 15) away from the cartridge end of the injection device 1. The axial load acts to maintain engagement of the ratchet teeth 19a, 19b of the clutch plate 16 and the drive member 8. The torque required to overhaul the ratchet teeth is resultant from the axial load applied by the return spring 13, the clockwise ramp angle of the ratchet, the friction coefficient between the mating surfaces and the mean radius of the ratchet features.

As the user rotates the dial grip 14 sufficiently to increment the mechanism by one unit, the dial member 6 rotates relative to the drive member 8 by one set of ratchet teeth 19a, 19b. At this point the ratchet teeth reengaged into the next detented position. An audible click is generated by the ratchet reengagement, and tactile feedback is given by the change in torque input required. Thus, the second clutch 19 forms a ratchet clicker.

Relative rotation of the dial member 6 and the drive member 8 causes a last dose nut 11 to travel along its threaded path towards its last dose abutment on the dial member 6. Rotation of the dial member 6 further generates rotation in the display member 7, which travels along its helical path defined by its interface with the inner housing 5. The dose marking corresponding to x units become aligned to the window 17 in the outer housing 4. The device is now set to deliver x units of liquid medicament.

With no user torque applied to the dial grip 14, the dial member 6 is now prevented from rotating under the action of the torque applied by the drive spring 12, solely by the ratchet engagement between the clutch plate 16 and the drive member 8 (second clutch 19). The torque necessary to overhaul the ratchet in the anti-clockwise direction is resultant from the axial load applied by the return spring 13, the anti-clockwise ramp angle of the ratchet, the friction coefficient between the mating surfaces and the mean radius of the ratchet features. The torque necessary to overhaul the ratchet must be greater than the torque applied to the dial member 6 (and hence clutch plate 16) by the drive spring 12. The ratchet ramp angle is therefore increased in the anti-clockwise direction to ensure this is the case.

The user may now choose to increase the selected dose by continuing to rotate the dial grip 14 in the clockwise direction. The process of overhauling the ratchet interfaces between the dial member 6 and the drive member 8 is repeated for each dose unit. Additional energy is stored within the drive spring 12 for each dose unit and audible and tactile feedback is provided for each unit dialed by the reengagement of the ratchet teeth. The torque required to rotate the dial grip 14 increases as the torque required to wind up the drive spring 12 in-

creases. The torque required to overhaul the ratchet in the anti-clockwise direction must therefore be greater than the torque applied to the dial member 6 by the drive spring 12 when the maximum dose has been reached.

5 If the user continues to increase the selected dose until the maximum dose limit is reached, the display member 7 engages with its maximum dose abutment on the outer housing 4, which prevents further rotation of the display member 7, dial member 6, clutch plate 16 and dial grip 14. At this point the maximum dose marking on the display member 7 is aligned to the window 17 in the outer housing 4.

10 Depending on how many units have already been delivered by a drive mechanism, during selection of a dose, the last dose nut 11 may contact its last dose abutment, i.e. the end stop with the dial member 6. The abutment prevents further relative rotation of the dial member 6 and the drive member 8 and therefore limits the dose that can be selected. The position of
15 the last dose nut 11 is determined by the total number of relative rotations between the dial member 6 and the drive member 8, which have occurred each time the user sets a dose.

With the mechanism in a state in which a dose has been selected, the user is able to deselect or reset any number of units from this dose. Deselecting a dose is achieved by the user
20 rotating the dial grip 14 anti-clockwise. The torque applied to the dial grip 14 by the user is sufficient, when combined with the torque applied by the drive spring 12 to overhaul the ratchet 19 between the clutch plate 16 and the drive member 8 in the anti-clockwise direction. When the ratchet is overhauled, anti-clockwise rotation occurs in the dial member 6 (via the clutch plate 16) which returns the display member 7 towards the zero dose position, and
25 unwinds the drive spring 12. The relative rotation between the dial member 6 and the drive member 8 causes the last dose nut 11 to return along its helical path, away from the last dose abutment.

With the mechanism in a state in which a dose has been selected, the user is able to activate
30 the drive mechanism to commence delivery of a dose (dose dispensing). Delivery of a dose is initiated by the user depressing the dose button 15 on the top (proximal end) of the drive mechanism. When the dose button is depressed, it moves axially, acting on the clutch plate 16, which in turn acts on the drive member 8. The clutch plate 16 disengages its spline teeth from the dial grip 14 and after that the drive member 8 disengages its spline teeth (first clutch
35 18) from the inner housing 5.

When the splined interface of the first clutch 18 between the inner housing 5 and the drive member 8 disengages, the interface which prevents rotation of the drive member 8 during selection of a dose is removed. The torque applied to the dial member 6 from the drive spring 12 is transmitted, via the ratchet interface of the second clutch 19 into the drive member 8.

5 This torque causes the drive member 8 and hence, due to its relative engagement with the inner housing 5, advancement of the lead screw 9. Axial displacement of the lead screw 9 forces liquid medicament to be delivered from the mechanism, by the action of the bearing 10 which contacts and displaces the bung within the cartridge 3.

10 The ratchet feature 20 of the inner housing 5 comprises a clicker arm 20a. As can be taken from Figure 6, the clicker arm 20a is a compliant cantilever beam integrated into the inner housing 5, which interfaces radially with the spline ratchet teeth 18b in the drive member 8. The ratchet teeth 18b spacing corresponds to the drive member 8 rotation required to deliver a single dose unit. During dispense, as the drive member 8 rotates, the spline features en-
15 gage with the clicker arm 20a to produce an audible click with each dose unit delivered. The torque required to overhaul the clicker arm is resultant from the ratchet teeth profile, the stiffness of the cantilever beam and the nominal interference between the clicker arm and the ratchet. The clicker arm interface is designed such that the torque required to overhaul is significantly less than the torque provided by the drive spring 12.

20 The rotation of the dial member 6 also causes the display member 7 to return along its helical path, relative to the inner housing 5, towards the zero dose abutment. Delivery of a dose continues via the mechanical interactions described above while the user continues to depress the dose button 15. If the user releases the dose button 15, the return spring 13 re-
25 turns the dose button 15 to its at rest position via the drive member 8 and the clutch plate 16 such that the drive member 8 becomes rotationally constrained and delivery of a dose is halted.

30 With the dose button 15 depressed, delivery of a dose continues until the display member 7 reaches its zero dose abutment with the inner housing 5. The torque applied to the dial member 6 is reacted by the abutment of the display member 7 and the dial member 6, wherein the clutch plate 16 and the drive member 8 are prevented from rotating further. During delivery of a dose, the drive member 8 and the dial member 6 rotate together, so that no relative motion in the last dose nut 11 occurs. The last dose nut 11 therefore travels
35 towards its abutment on the dial member 6 during dose setting only and travels away from the end stop during dose resetting.

Once the delivery of a dose is stopped by the display member 7 returning to the zero dose abutment, the user may release the dose button 15 which will reengage the first clutch 18 between the inner housing 5 and the drive member 8. The mechanism is now returned to the at rest condition.

It is possible to angle the spline teeth 18a, 18b on either the drive member 8 or inner housing 5 so that when the dose button 15 is released the reengagement of the spline teeth fractionally backwind the drive member 8 thereby removing the engagement of the display member 7 to the zero dose stop abutment in the inner housing 5. This removes the effect of clearances in the drive mechanism (for example due to tolerances) which could otherwise lead to slight advancement of the lead screw 9 and medicament dispense when the drive mechanism is dialled for the subsequent dose. This is due to the zero dose stop of the display member 7 no longer restraining the mechanism and instead the restraint returning to the splines between the drive member 8 and the inner housing 5.

A second embodiment of a drive mechanism which is suitable for an injection device 101 is shown in Figures 7 to 17. The injection device 101 comprises a cartridge holder 102, a cartridge 103 containing a medicament, optionally a cap (not shown) and a drive mechanism. The drive mechanism comprises an outer housing 104 with a window 117, an inner housing 105, a dial member 106 (dial sleeve), a display member 107 (number sleeve), a drive member 108 (drive sleeve), a lead screw 109, a bearing 110, a nut 111, a torsion spring 112, a dial grip 114, a first clutch 118, a second clutch 119, a ratchet feature 120, a clutch spring 121, a trigger clutch 122, a trigger 123 and a trigger cover 124.

Similar to the first embodiment, all components, except for the trigger 123 and the trigger cover 124, are located concentrically about a common principal axis of the drive mechanism.

The dial grip 114 is axially constrained to the outer housing 104. It is rotationally constrained, via a splined interface, to the dial member 106. As shown in Figure 11, the dial member 106 is coupled to the drive member 108 via a ratchet interface (second clutch 119), which occurs on an axial abutment. The ratchet provides a detented position between the dial member 106 and the drive member 108 corresponding to each dose unit, and engages different ramped tooth angles during clockwise and anti-clockwise relative rotation. Corresponding ratchet teeth 119a, 119b are provided on facing surfaces of the dial member 106 and the drive member 108.

The display member 107 is rotationally constrained, via a splined interface, to the dial member 106. It is constrained to move along a helical path, relative to the inner housing 105, via a threaded interface. The display member 107 is marked with a sequence of numbers, which are visible through the window 117 in the outer housing 104, to denote the dialled dose of medicament.

The last dose nut 111 is located between the dial member 106 and the drive member 108. It is rotationally constrained to the drive member 108, via a splined interface. It moves along a helical path relative to the dial member 106, via a threaded interface, when relative rotation occurs between the dial member 106 and drive member 108.

The drive member 108 extends from the interface with the dial member 106 down to a ratchet interface with the inner housing 105, which occurs on an axial abutment. The ratchet interface defines the axial position of the drive member 108 at the end of dose delivery, and is included to improve dose accuracy. The drive member 108 is rotationally constrained to the trigger clutch 122, via engagement of a set of spline teeth, when the trigger 123 is activated. It provides a clicker arm 120a, which acts radially against a set of ratchet teeth 120b in the inner housing 105. It moves along a helical path relative to the lead screw 109, via a threaded interface. The drive member 108 provides an axial abutment with the inner housing 105, which engages when the drive mechanism dispenses, to react the force applied by the lead screw 109 to the cartridge 103.

The torsion spring 112 is attached at one end to the inner housing 105 and at the other end to the dial member 106. The attachments at both ends are configured to transfer tangential forces, resulting from torsion of the spring 112, and axial forces along the primary axis of the drive mechanism (longitudinal axis). The torsion spring 112 is pre-wound upon assembly, such that it applies a torque to the dial member 106 when the mechanism is at zero units dialled. The action of rotating the dial grip 114, to set a dose, rotates the dial grip 114 relative to the inner housing 105, and winds up the torsion spring 112. The torsion spring 112 is designed in such a way as to exert an axial force which acts to pull the dial member 106 towards the inner housing 105.

The lead screw 109 is rotationally constrained to the inner housing 105 via a splined interface. The lead screw 109 is forced to move axially relative to the inner housing 105, through its threaded interface to the drive member 108, when the drive member 108 moves relative to

the inner housing 105. The bearing 110 (washer) is axially constrained to the lead screw 109 and acts on the bung within the liquid medicament cartridge 103.

The inner housing 105 is rigidly constrained to the outer housing 104. As shown in Figures 5 10a, 10b the axial abutment with the drive member 108 is provided by a pair of compliant arms 105a which deflect during assembly. A pair of abutment features 105b, 105c is provided, at either end of the threaded interface with the display member 107, which limit the range of travel of the display member 107. These abutments 105b, 105c provide the zero dose and maximum dose stops. The inner housing 105 provides a rotational constraint to the trigger 10 clutch 122, and provides an axial abutment which reacts the axial force generated by the clutch spring 121. The axial position of the trigger clutch 122 is defined by the action of the clutch spring 121, which forces the trigger clutch 122 towards the cartridge end (distal end) of the drive mechanism, and its abutment with the trigger 123. When axially positioned in its at rest position, the trigger clutch 122 engages with the spline teeth on the drive member 108 15 which constrains the rotation of the drive member 108. The spline teeth 118a on the trigger clutch 122 and the corresponding spline teeth 118b on the drive member 108 form the first clutch 118. Engagement and disengagement of the first clutch 118 is shown in Figures 12a to 13b in more detail.

20 The clutch spring 121 is located between the inner housing 105 and the trigger clutch 122 and acts to force the trigger clutch 122 towards the cartridge end of the drive mechanism. The trigger 123 is constrained to pivot in the outer housing 104. It has an integral spring element, which acts to rotate the trigger 123 away from the outer housing 104. When the trigger 123 is depressed, an abutment is created with the trigger clutch 122, which moves the 25 trigger clutch 122 axially towards the inner housing 105.

The outer housing 104 provides location for the liquid medication cartridge 103, the pivot for the trigger 123, an interface to rigidly constrain the inner housing 105, a window 117 through which the dose number on the display member 107 can be viewed, and a groove on its 30 external surface to axially retain the dial grip 114. The trigger cover 124 may clip into the outer housing 104, and retains the trigger 123 within its pivot interface with the outer housing 104. The removable cap fits over the cartridge holder element 102 and is retained onto the outer housing 104 via clips when the drive mechanism is not in use. When the cap is fitted onto the outer housing 104, a mechanical interlock is created with the trigger 123, which 35 prevents the trigger from being depressed from its at rest position.

With the device in the at rest condition, the display member 107 is positioned against its zero dose abutment with the inner housing 105 and the trigger 123 is not depressed. Dose marking '0' on the display member 107 is visible through the window 117 on the outer housing 104. The torsion spring 112, which has a number of pre-wound turns applied to it during assembly of the drive mechanism, applies a torque to the dial member 106. The dial member 106 is prevented from rotating, under the action of this torque, by its ratchet interface (second clutch 119) with the drive member 108, and by the abutment of the display member 107 against the inner housing 105. The drive member 108 is prevented from rotating by the interlock provided by the engagement of splined teeth 118a, 118b on the drive member 108 and trigger clutch 122, respectively.

The user selects a variable dose of liquid medicament by rotating the dial grip 114 clockwise, which generates an identical rotation in the dial member 106. Rotation of the dial member 106 causes wind up of the torsion spring 112, increasing the energy stored within the torsion spring 112. The drive member 108 is still prevented from rotating, due to the engagement of its splined teeth 118b with the trigger clutch 122. Relative rotation must therefore occur between the dial member 106 and drive member 108, via the ratchet interface (second clutch 119).

The user torque required to rotate the dial grip 114 is a sum of torque required to wind up the torsion spring 112, and the torque required to overhaul the ratchet feature. The torsion spring 112 is designed such that it applies an axial load to the dial member 106. The axial load acts to maintain the detented engagement of the dial member 106 and drive member 108. The torque required to overhaul the ratchet is resultant from the axial load applied by the torsion spring 112, the clockwise ramp angle of the ratchet, the friction coefficient between the mating surfaces and the mean radius of the ratchet feature.

As the user rotates the dial grip 114 sufficiently to increment the mechanism by 1 unit, the dial member 106 rotates relative to the drive member 108 by 1 set of ratchet teeth 119a, 119b. At this point the ratchet teeth 119a, 119b reengage into the next detented position. An audible click is generated by the ratchet re-engagement, and tactile feedback is given by the change in torque profile.

Relative rotation of the dial member 106 and the drive member 108 causes the last dose nut 111 to travel along its threaded path, towards its last dose abutment.

Rotation of the dial member 106 generates rotation in the display member 107, which travels along its helical path defined by its interface with the inner housing 105. The dose marking corresponding to 1 unit becomes aligned to the window 117 in the outer housing. The device is now set to deliver 1 unit of liquid medicament.

5

With no user torque applied to the dial grip 114, the dial member 106 is now prevented from rotating, under the action of the torque applied by the torsion spring 112, solely by the ratchet engagement between the dial member 106 and the drive member 108. The torque necessary to overhaul the ratchet in the anti-clockwise direction is resultant from the axial load applied by the torsion spring 112, the anti-clockwise ramp angle of the ratchet, the friction coefficient between the mating surfaces and the mean radius of the ratchet feature. The torque necessary to overhaul the ratchet must be greater than the torque applied to the dial member 106 by the torsion spring 112. The ratchet ramp angle is therefore increased in the anti-clockwise direction to ensure this is the case.

15

The user may now choose to increase the selected dose by continuing to rotate the dial grip 114 in the clockwise direction. The process of overhauling the ratchet interfaces (teeth 119a, 119b) between the dial member 106 and drive member 108 is repeated for each dose unit. Additional energy is stored within the torsion spring 112 for each dose unit and audible and tactile feedback is provided for each unit dialled by the re-engagement of the ratchet teeth 119a, 119b. Thus, the second clutch 119 forms a clicker ratchet. The torque required to rotate the dial grip 114 increases as the torque required to wind up the torsion spring 112 increases. The torque required to overhaul the ratchet in the anti-clockwise direction must therefore be greater than the torque applied to the dial member 106 by the torsion spring 112 when the maximum dose has been reached.

20

25

If the user continues to increase the selected dose until the maximum dose limit is reached, the display member 107 engages with its maximum dose abutment 105c on the inner housing 105, which prevents further rotation of the display member 107, dial member 106 and dial grip 114. At this point the maximum dose marking on the display member 107 is aligned to the window 117.

30

Depending on how many units have already been delivered by the drive mechanism, during selection of a dose, the last dose nut 111 may contact its last dose abutment with the dial member 106. The abutment prevents further relative rotation of the dial member 106 and the drive member 108, and therefore limits the dose that can be selected. The position of the last

35

dose nut 111 is determined by the total number of relative rotations between the dial member 106 and drive member 108, which have occurred each time the user sets a dose.

5 With the drive mechanism in a state in which a dose has been selected, the user is able to deselect any number of units from this dose. Deselecting a dose is achieved by the user rotating the dial grip 114 anti-clockwise. The torque applied to the dial grip 114 by the user is sufficient, when combined with the torque applied by the torsion spring 112, to overhaul the ratchet 119a, 119b between the dial member 106 and drive member 108 in the anti-clockwise direction. When the ratchet is overhauled, anti-clockwise rotation occurs in the dial member 106, which returns the display member 107 towards the zero dose position, and unwinds the torsion spring 112. The relative rotation between the dial member 106 and drive member 108 causes the last dose nut 111 to return along its helical path, away from the last dose abutment 105c.

15 With the mechanism in a state in which a dose has been selected, the user is able to activate the drive mechanism to commence delivery of a dose. Delivery of a dose is initiated by the user depressing the trigger 123 on the side of the drive mechanism. If the cap is fitted to the drive mechanism, a mechanical interlock is provided which prevents depression of the trigger 123, and therefore prevents the drive mechanism from dispensing a dose. Selection of a dose can therefore be completed with the cap fitted, and this eliminates the risk of the drive mechanism dispensing a dose by unintentional depression of the trigger 123 while the user is selecting the dose. In addition, this feature allows the device to be stored or carried with a pre-selected dose, perhaps by a carer or parent, ready to use without dialling.

25 Once the cap is removed, depression of the trigger 123 can occur. As the trigger is depressed, an abutment is created with the trigger clutch 122 which acts to move the trigger clutch axially away from the cartridge 103, against the action of the clutch spring 121. When the trigger 123 is fully depressed, sufficient axial travel has occurred in the trigger clutch 122 to remove the engagement of the spline teeth 118a, 118b on the trigger clutch 122 and the drive member 108.

35 When this splined interface between the trigger clutch 122 and the drive member 108 disengages, the interface which prevented rotation of the drive member 108 during selection of a dose has been removed. The torque applied to the dial member 106 from the torsion spring 112 is transmitted, via the ratchet interface (second clutch 119), into the drive member 108. This torque acts to overhaul the clicker arm 120a between the drive member 108 and the

inner housing 104, and the axial ratchet interface between the drive member 108 and the inner housing 104.

As shown in Figures 14 and 17, the clicker arm 120a is a compliant cantilever beam integrated into the drive member 108, which interfaces radially with a set of ratchet teeth 120b in the inner housing 105. The ratchet teeth spacing corresponds to the drive member 108 rotation required to deliver a single dose unit. The clicker arm 120a produces an audible click to the user, corresponding to each dose unit delivered. The torque required to overhaul the clicker arm 120a is resultant from the ratchet teeth 120b profile, the stiffness of the cantilever beam and the nominal interference between clicker arm and ratchet. The clicker arm interface is designed such that the torque required to overhaul is significantly less than the torque provided by the torsion spring 112.

As shown in Figures 15 to 17, further ratchet 125 is provided as helical stop features between a shoulder of the inner housing 105 and an end face of the drive member 108. These helical stop features comprise corresponding teeth 125a, 125b provided on the inner housing and the drive member. The torque required to overhaul the helical stop features 125, between the drive member 108 and the inner housing 105, is resultant from the axial load applied by the torsion spring 112, the ramp angle of the helical stop features (teeth 125a, 125b), the friction coefficient between the mating surfaces and the mean radius of the helical stop features. The helical stop features 125 are designed such that the torque required to overhaul is significantly less than the torque provided by the torsion spring 112.

The torque applied to the drive member 108 by the torsion spring 112 is sufficient to overhaul the clicker arm 120a and helical stop features 125. The drive member 108 starts to rotate along a helical path defined by the ramp profile of the helical stop features. The ramp profile is matched to the helical pitch of the threaded interface between the drive member 108 and the lead screw 109, such that the drive member 108 travels helically up the lead screw 109, which remains stationary relative to the inner housing 105.

The dial member 106 rotates with the drive member 108, which causes the display member 107 to return along its helical path, relative to the inner housing 105, towards the zero dose abutment 105b.

The spacing of the teeth 125a, 125b (helical stop features) corresponds to the drive member 108 rotation required to deliver a single unit of liquid medicament. When the drive member 108 has rotated by 1 unit, axial separation is generated between the teeth 125a, 125b corresponding to the lead screw 109 displacement required to dispense 1 unit. The axial force
5 provided by the torsion spring 112, which is applied to the drive member 108, acts directly on the lead screw 109, tending to displace the drive member 108 and the lead screw 109 to re-engage the helical stop features 125.

If a greater axial force is required to displace the lead screw 109 than directly provided by the
10 torsion spring 112, the drive member 108 continues to rotate along its helical path, defined by the threaded interface with the lead screw 109, until an axial abutment is created between the drive member 108 and the inner housing 105. The drive member 108 is now constrained axially, and further helical motion between the drive member 108 and lead screw 109 results in rotation only of the drive member 108 causing axial motion of the lead screw 109 relative
15 to the inner housing 105.

The torque applied to the drive member 108 from the torsion spring 112 is converted into an axial force via the threaded interface with the lead screw 109. The axial force generated is sufficient to displace the lead screw 109 relative to the inner housing 105. Axial displacement
20 of the lead screw 109 forces liquid medicament to be delivered from the drive mechanism, by the action of the washer bearing 110, which is axially constrained to the lead screw 109, contacting and displacing the bung within the cartridge 103.

Delivery of a dose continues via the mechanical interactions described above while the user
25 continues to depress the trigger 123. If the user releases the trigger 123, the integral spring returns the trigger 123 to its at rest position and the clutch spring 121 forces the splined teeth 118a on the trigger clutch 122 to re-engage with the teeth 118b on the drive member 108. The drive member 108 becomes rotationally constrained and delivery of a dose is halted.

30 With the trigger 123 depressed, delivery of a dose continues until the display member 107 reaches the zero dose abutment 105b with the inner housing 105. The torque applied to the dial member 108 is reacted by the abutment of the display member 107 and the dial member 106 and drive member 108 are prevented from rotating further.

35 The axial force from the torsion spring 112 is still applied to the dial member 106 and drive member 108, and the drive member 108 and lead screw 109 displace axially together to

complete the dose, which re-engages the axial ratchet or helical stop interface 125 between the drive member 108 and inner housing 105. The ramp interface 125 improves dose accuracy as it provides a consistent lead screw axial position which is insensitive to variation in the rotational position of the drive member as defined by the first clutch 118. This removes
5 the effect of clearances in the drive mechanism (for example due to tolerances) which could otherwise lead to slight advancement of the lead screw 109 and medicament dispense when the drive mechanism is dialled for the subsequent dose. This is due to the zero dose stop of the display member 107 no longer restraining the mechanism and instead the restraint re-
10 turning to the splines between the drive member 108 and the inner housing 105.

During delivery of a dose, the drive member 108 and dial member 106 rotate together, so that no relative motion in the last dose nut 111 occurs. The last dose nut 111 therefore travels towards its abutment on the dial member 106 during dialling only.

15 Once the delivery of a dose is stopped, by the display member 107 returning to the zero dose abutment 105b, the user may release the trigger 123, which will re-engage the trigger clutch spline teeth 118a with the drive member 108. The drive mechanism is now returned to the at rest condition.

20 The drive mechanism enables a one piece body construction, as all coaxial components can be installed into the outer housing from the dial grip end. The mechanism allows a sub-assembly containing the pre-wound torsion spring 112 to be assembled, prior to final assembly into a device containing the liquid medicament cartridge 103. The washer bearing 110 provides an abutment which retains the trigger clutch 122 in engagement with the drive
25 member 108 at the sub-assembly stage. Once fully assembled, the trigger clutch 122 is restrained by abutments with the outer housing 104 or the trigger 123.

Reference Numerals:

5	1, 101	injection device
	2, 102	cartridge holder
	3, 103	cartridge
	4, 104	outer housing (body)
	5, 105	inner housing
10	105a	compliant arm
	105b	zero dose abutment
	105c	maximum dose abutment
	6, 106	dial member (dose dial sleeve)
	7, 107	display member (number sleeve)
15	8, 108	drive member (drive sleeve)
	9, 109	lead screw
	10, 110	bearing (washer)
	11, 111	last dose nut
	12, 112	drive spring (torsion spring)
20	13	return spring
	14, 114	dial grip
	15	dose button
	16	clutch plate
	17, 117	window
25	18, 118	first clutch
	18a, 18b	spline teeth
	118a, 118b	spline teeth
	19, 119	second clutch (clicker ratchet)
	19a, 19b	ratchet teeth
30	119a, 119b	ratchet teeth
	20, 120	ratchet (clicker)
	20a, 120a	clicker arm
	120b	clicker teeth
	121	clutch spring
35	122	trigger clutch
	123	trigger

124	trigger cover
125	helical stop features
125a, 125b	teeth

Claims:

5

1. Drive mechanism for an injection device, the mechanism comprising:

- a housing (4, 5; 104, 105),
 - an axially not moving dial member (6; 106),
 - a drive member (8; 108) engaging a lead screw (9; 109),
 - 10 - a first clutch (18; 118) rotationally coupling the drive member (8; 108) and the housing (4, 5; 104, 105) in a coupled state and allowing relative rotation between the drive member (8; 108) and the housing (4, 5; 104, 105) in a de-coupled state,
 - a second clutch (19; 119) rotationally coupling the drive member (8; 108) and the dial member (6; 106) in a coupled state and allowing relative rotation between the drive member (8; 108) and the dial member (6; 106) in a de-coupled state,
 - 15 - a nut (11, 111), which is rotationally constrained to the drive member (8; 108) and threadedly engaged to the dial member (6; 106), and
 - an end stop limiting movement of the nut (11; 111),
- characterized in that during dose setting and dose resetting the dial member (6; 106) and the drive member (8; 108) do not move axially with respect to the housing (4, 5; 104, 105).

20

2. Drive mechanism according to claim 1, wherein the nut (11; 111) is guided axially displaceable on the drive member (8; 108).

25

3. Drive mechanism according to claim 1 or 2, wherein the nut (11; 111) has an external thread engaging an internal thread of the dial member (6; 106) such that relative rotation between the drive member (8; 108) and the dial member (6; 106) during dose setting causes the nut (11; 111) to move towards the end stop.

30

4. Drive mechanism according to claim 3, wherein the internal thread of the dial member (6; 106) comprises a plurality of thread segments.

5. Drive mechanism according to any of claims 1 to 4, wherein the end stop is provided on the dial member (6; 106).

35

6. Drive mechanism according to any of claims 1 to 4, wherein the end stop is provided on the drive member (8; 108).

7. Drive mechanism according to any of claims 1 to 6, wherein during dose setting and dose resetting the first clutch (18; 118) is in its coupled state and the second clutch (19; 119) is in its de-coupled state.

8. Drive mechanism according to any of claims 1 to 7, wherein during dose setting and dose resetting a spring (12; 13; 112; 121) biases the first clutch (18; 118) in its coupled state and/or pulls the second clutch (19; 119) in its de-coupled state.

9. Drive mechanism according to any of claims 1 to 8, wherein the second clutch (19; 119) comprises a ratchet clicker with teeth (19a, 19b; 119a, 119b) having in the clockwise and the anti-clockwise direction different ramped tooth angles such that the teeth (19a, 19b; 119a, 119b) are allowed to override each other in the de-coupled state of the second clutch (19; 119) with a different resistance in the clockwise and the anti-clockwise direction, and wherein during dose setting and dose resetting the teeth (19a, 19b; 119a, 119b) of the second clutch (19; 119) engage in the de-coupled state but are allowed to override each other by an axial movement against the force of an elastic member.

10. Drive mechanism according to any of claims 1 to 9, wherein during dose dispensing the first clutch (18; 118) is in its de-coupled state and the second clutch (19; 119) is in its coupled state.

11. Drive mechanism according to any of claims 1 to 10, wherein the drive member (8; 108) and the dial member (6; 106) rotate relative to each other during dose setting and dose resetting, and wherein the drive member (8; 108) and the dial member (6; 106) rotate together during dose dispensing.

12. Drive mechanism according to any of claims 1 to 11, wherein the first clutch (18; 118) is coupled and de-coupled by axially displacing the drive member (8; 108) relative to the housing (4, 5; 104, 105).

13. Drive mechanism according to any of claims 1 to 11 further comprising a trigger clutch (122) which is held rotationally fixed and axially displaceable within the housing (4, 5; 104,

105), wherein the first clutch (18; 118) is de-coupled by axially displacing the trigger clutch (122) relative to the drive member (8; 108).

5 14. Injection device comprising a drive mechanism according to any of claims 1 to 13 and a cartridge (3; 103) containing a medicament, wherein the nut (11; 111) prevents setting of a dose exceeding the amount of a medicament in the cartridge (3; 103).

10 15. Injection device according to claim 14, wherein the end stop defines the length of a track on which the nut (11; 111) travels during dose setting, and wherein the length of the track corresponds to the total amount of medicament in the cartridge (3; 103).

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5a




Fig. 5b




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10a




Fig. 10b




Fig. 11




Fig. 17




Fig. 12a




Fig. 13a




Fig. 12b




Fig. 13b




Fig. 14




Fig. 15





Fig. 16a

Fig. 16b

Fig. 16c



INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2014/068655

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61M5/315

ADD. A61M5/20 A61M5/24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2009/105909 A1 (TECPHARMA LICENSING AG [CH]; EICH ADRIAN [CH]; HORISBERGER AURELE [CH]) 3 September 2009 (2009-09-03) abstract; figure 1 page 11, line 9 - page 17, line 12 -----	1-15
X	WO 2008/031235 A1 (TECPHARMA LICENSING AG [CH]; KOHLBRENNER PHILIPPE [CH]; STETTLER PETER) 20 March 2008 (2008-03-20) the whole document -----	1-15
X	WO 2012/125876 A1 (BECTON DICKINSON CO [US]; QUINN MICHAEL [US]; CRONENBERG RICHARD [US]) 20 September 2012 (2012-09-20) abstract; figures 1-16 paragraphs [0002], [0093] - [0100], [0103] - [0106] ----- -/--	1-15



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

21 October 2014

Date of mailing of the international search report

30/10/2014

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Petersch, Bernhard

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2014/068655

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2009/070911 A1 (TECPHARMA LICENSING AG [CH]; WITTMANN JUERGEN [CH]; HORISBERGER AURELE) 11 June 2009 (2009-06-11) abstract; figure 1 page 12, line 10 - page 16, line 18 -----	1-15
X	WO 2011/039207 A1 (SANOFI AVENTIS DEUTSCHLAND [DE]; VEASEY ROBERT [GB]; BILTON SIMON LEWI) 7 April 2011 (2011-04-07) abstract; figures 1-5 page 3, line 31 - page 4, line 4 page 13, line 11 - page 14, line 2 -----	1-15
X	US 2009/275916 A1 (HARMS MICHAEL [DE] ET AL) 5 November 2009 (2009-11-05) the whole document -----	1-15
X	WO 2010/139645 A1 (SANOFI AVENTIS DEUTSCHLAND [DE]; PLUMPTRE DAVID [GB]) 9 December 2010 (2010-12-09) the whole document -----	1-15
X	WO 2007/030957 A1 (TECPHARMA LICENSING AG [CH]; BURREN STEFAN [CH]; KOHLBRENNER PHILIPPE) 22 March 2007 (2007-03-22) the whole document -----	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2014/068655

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 2009105909	A1	03-09-2009	CN	102014991 A		13-04-2011
			DE	102008011885 A1		10-09-2009
			EP	2262553 A1		22-12-2010
			TW	200942284 A		16-10-2009
			US	2011054412 A1		03-03-2011
			WO	2009105909 A1		03-09-2009

WO 2008031235	A1	20-03-2008	CN	101563123 A		21-10-2009
			CN	101588830 A		25-11-2009
			CN	101594896 A		02-12-2009
			CN	101594897 A		02-12-2009
			CN	101594898 A		02-12-2009
			DE	102007022791 A1		27-03-2008
			EP	2066373 A1		10-06-2009
			EP	2073872 A1		01-07-2009
			EP	2076302 A1		08-07-2009
			EP	2076303 A1		08-07-2009
			EP	2077878 A1		15-07-2009
			JP	4955772 B2		20-06-2012
			JP	2010503430 A		04-02-2010
			JP	2010503431 A		04-02-2010
			JP	2010503432 A		04-02-2010
			JP	2010503433 A		04-02-2010
			JP	2010503434 A		04-02-2010
			US	2009247951 A1		01-10-2009
			US	2009247959 A1		01-10-2009
			US	2009247960 A1		01-10-2009
			US	2009254035 A1		08-10-2009
			US	2009254044 A1		08-10-2009
			US	2012197213 A1		02-08-2012
			WO	2008031235 A1		20-03-2008
			WO	2008031236 A1		20-03-2008
			WO	2008031237 A1		20-03-2008
			WO	2008031238 A1		20-03-2008
			WO	2008031239 A1		20-03-2008

WO 2012125876	A1	20-09-2012	AU	2012229074 A1		10-10-2013
			CA	2829850 A1		20-09-2012
			CN	103492004 A		01-01-2014
			EP	2686041 A1		22-01-2014
			JP	2014513588 A		05-06-2014
			SG	193448 A1		30-10-2013
			US	2014046268 A1		13-02-2014
			WO	2012125876 A1		20-09-2012

WO 2009070911	A1	11-06-2009	DE	102007058659 A1		24-09-2009
			EP	2227277 A1		15-09-2010
			US	2011004166 A1		06-01-2011
			WO	2009070911 A1		11-06-2009

WO 2011039207	A1	07-04-2011	AR	078457 A1		09-11-2011
			AU	2010303051 A1		19-04-2012
			CA	2773460 A1		07-04-2011
			CN	102548601 A		04-07-2012
			DK	2482892 T3		09-12-2013
			EP	2482892 A1		08-08-2012
			ES	2435296 T3		18-12-2013
			HK	1168821 A1		04-04-2014

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2014/068655

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
		JP 2013506446 A	28-02-2013	
		KR 20120091009 A	17-08-2012	
		NZ 599030 A	28-02-2014	
		RU 2012117616 A	10-11-2013	
		TW 201127435 A	16-08-2011	
		US 2013035647 A1	07-02-2013	
		WO 2011039207 A1	07-04-2011	

US 2009275916	A1	05-11-2009	AR 071524 A1	23-06-2010
			AU 2009242697 A1	05-11-2009
			CA 2723266 A1	05-11-2009
			CN 102083489 A	01-06-2011
			CR 11702 A	10-01-2011
			DK 2274032 T3	29-10-2012
			EP 2274032 A1	19-01-2011
			ES 2392667 T3	12-12-2012
			HK 1153156 A1	14-03-2014
			JP 5478607 B2	23-04-2014
			JP 2011519600 A	14-07-2011
			KR 20110010705 A	07-02-2011
			MY 149438 A	30-08-2013
			NZ 588810 A	25-01-2013
			PA 8825101 A1	16-12-2009
			PE 03352010 A1	07-05-2010
			PT 2274032 E	24-10-2012
			RU 2010149251 A	10-06-2012
			SI 2274032 T1	31-12-2012
			TW 201004669 A	01-02-2010
			UA 99367 C2	10-08-2012
			US 2009275916 A1	05-11-2009
			US 2014243784 A1	28-08-2014
			UY 31795 A	14-12-2009
			WO 2009132778 A1	05-11-2009

WO 2010139645	A1	09-12-2010	AU 2010255820 A1	22-12-2011
			CA 2762043 A1	09-12-2010
			CN 102458535 A	16-05-2012
			EP 2437829 A1	11-04-2012
			JP 2012528633 A	15-11-2012
			KR 20120028316 A	22-03-2012
			NZ 596701 A	28-03-2013
			RU 2011154135 A	20-07-2013
			SG 176076 A1	29-12-2011
			US 2010324494 A1	23-12-2010
			US 2012165751 A1	28-06-2012
			WO 2010139645 A1	09-12-2010

WO 2007030957	A1	22-03-2007	AT 415991 T	15-12-2008
			AU 2006291940 A1	22-03-2007
			CN 101262899 A	10-09-2008
			DE 102005060929 A1	15-03-2007
			DK 1926514 T3	06-04-2009
			EP 1926514 A1	04-06-2008
			JP 4681055 B2	11-05-2011
			JP 2009507581 A	26-02-2009
			US 2008306445 A1	11-12-2008
			WO 2007030957 A1	22-03-2007
